Table 2 Overall survival and progression-free survival at 6 and 12 months compared between the 2019 and 2020 cohorts of Patients with WHO Grade 3 gliomas according to Kaplan–Meier estimation.

From: Impact of the SARS-CoV-2 pandemic on the survival of patients with high-grade glioma and best practice recommendations

WHO 3

Treatment year

P

Total

2019

2020

OS-6 (n; %)

21 (95.7)

8 (100.0)

13 (93.3)

.502

OS-12 (n; %)

16 (90.6)

7 (100.0)

9 (85.6)

.329

PFS-6 (n; %)

18 (95.0)

6 (100.0)

12 (92.3)

.452

PFS-12 (n; %)

15 (87.7)

6 (100.0)

9 (79.1)

.142

  1. OS—overall survival, PFS—progression-free survival, n—number.
Back to article page